Introduction: Temozolomide (TMZ) is a widely used chemotherapy agent for the treatment of malignant gliomas and other brain tumors. Despite its established therapeutic benefits, there is an ongoing need to understand better its safety profile, particularly in real-world clinical settings. This study aimed to identify critical adverse drug reactions (ADRs) associated with TMZ by utilizing the FDA Adverse Event Reporting System (FAERS) database, thereby providing valuable safety insights for clinical practice. Methods: We utilized the reported odds ratio, proportional reporting ratio, Bayesian Confidence Propagation Neural Network, and Empirical Bayes Geometric Mean as primary algorithms for disproportionality analysis. Adverse events (AEs) were classified as ADRs only upon meeting the criteria set by all four algorithms. To ensure the accuracy of our results, we meticulously excluded any AEs deemed unrelated to TMZ. Results: From October 2003 to September 2023, a total of 10,502,538 case reports and 9,073 cases explicitly attributed to TMZ were retrieved from the FAERS database. After applying our filters, 116 ADRs, each with a corresponding Preferred Term (PT), were identified across 18 System Organ Classes (SOCs). The identified ADRs associated with TMZ primarily involved bone marrow suppression, hepatotoxicity, and various infections, notably Pneumocystis jirovecii pneumonia. Furthermore, our analysis identified valuable ADRs not listed in the drug label, including congenital, familial, and genetic disorders at the SOC level, as well as unexpected ADRs at the PT level, such as seizures, pulmonary embolism, and sepsis. Conclusion: This real-world pharmacovigilance study has identified significant and previously unreported ADRs associated with TMZ. Further research for validation and resolution is urgently needed to guide the clinical application of TMZ, ensuring the safety and efficacy of its use in treating brain tumors.

1.
Koukourakis
GV
,
Kouloulias
V
,
Zacharias
G
,
Papadimitriou
C
,
Pantelakos
P
,
Maravelis
G
, et al
.
Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article
.
Molecules
.
2009
;
14
(
4
):
1561
77
.
2.
Tomar
MS
,
Kumar
A
,
Srivastava
C
,
Shrivastava
A
.
Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance
.
Biochim Biophys Acta Rev Cancer
.
2021
;
1876
(
2
):
188616
.
3.
Fabian
D
,
Guillermo Prieto Eibl
MDP
,
Alnahhas
I
,
Sebastian
N
,
Giglio
P
,
Puduvalli
V
, et al
.
Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): a review
.
Cancers
.
2019
;
11
(
2
):
174
.
4.
Zhang
J
,
Stevens
MFG
,
Bradshaw
TD
.
Temozolomide: mechanisms of action, repair and resistance
.
Curr Mol Pharmacol
.
2012
;
5
(
1
):
102
14
.
5.
Rezaee
A
,
Tehrany
PM
,
Tirabadi
FJ
,
Sanadgol
N
,
Karimi
AS
,
Ajdari
A
, et al
.
Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: function of non-coding RNAs
.
Biomed Pharmacother
.
2023
;
165
:
115187
.
6.
Malhotra
M
,
Chandrasekahran
A
,
Tonse
R
,
Jalali
R
,
Patil
VM
.
Cross-sectional study of temozolomide-induced chemotherapy-induced nausea and vomiting in patients with glioma
.
Clin Oncol (R Coll Radiol)
.
2019
;
31
(
1
):
e85
.
7.
Scaringi
C
,
De Sanctis
V
,
Minniti
G
,
Enrici
RM
.
Temozolomide-related hematologic toxicity
.
Onkologie
.
2013
;
36
(
7–8
):
444
9
.
8.
Wick
W
,
Platten
M
,
Meisner
C
,
Felsberg
J
,
Tabatabai
G
,
Simon
M
, et al
.
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
.
Lancet Oncol
.
2012
;
13
(
7
):
707
15
.
9.
Brown
EG
,
Wood
L
,
Wood
S
.
The medical dictionary for regulatory Activities (MedDRA)
.
Drug Saf
.
1999
;
20
(
2
):
109
17
.
10.
Evans
SJW
,
Waller
PC
,
Davis
S
.
Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
.
Pharmacoepidemiol Drug Saf
.
2001
;
10
(
6
):
483
6
.
11.
Rothman
KJ
,
Lanes
S
,
Sacks
ST
.
The reporting odds ratio and its advantages over the proportional reporting ratio
.
Pharmacoepidemiol Drug Saf
.
2004
;
13
(
8
):
519
23
.
12.
Bate
A
,
Lindquist
M
,
Edwards
IR
,
Olsson
S
,
Orre
R
,
Lansner
A
, et al
.
A Bayesian neural network method for adverse drug reaction signal generation
.
Eur J Clin Pharmacol
.
1998
;
54
(
4
):
315
21
.
13.
Dumouchel
W
.
Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system
.
The Am Statistician
.
1999
;
53
(
3
):
177
90
.
14.
Liu
S
,
Wei
M
,
Moore
R
,
Ganesan
V
,
Nelson
S
.
RxNorm: prescription for electronic drug information exchange
.
IT Prof
.
2005
;
7
(
5
):
17
23
.
15.
Dumouchel
W
.
Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system
.
Am Statistician
.
1999
;
53
(
3
):
177
90
.
16.
Farkouh
A
,
Riedl
T
,
Gottardi
R
,
Czejka
M
,
Kautzky-Willer
A
.
Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature
.
Adv Ther
.
2020
;
37
(
2
):
644
55
.
17.
Tan
AC
,
Ashley
DM
,
López
GY
,
Malinzak
M
,
Friedman
HS
,
Khasraw
M
.
Management of glioblastoma: state of the art and future directions
.
CA Cancer J Clin
.
2020
;
70
(
4
):
299
312
.
18.
Halani
SH
,
Babu
R
,
Adamson
DC
.
Management of glioblastoma multiforme in elderly patients: a review of the literature
.
World Neurosurg
.
2017
;
105
:
53
62
.
19.
Puca
AA
,
Lopardo
V
,
Montella
F
,
Di Pietro
P
,
Cesselli
D
,
Rolle
IG
, et al
.
The longevity-associated variant of BPIFB4 reduces senescence in glioma cells and in patients’ lymphocytes favoring chemotherapy efficacy
.
Cells
.
2022
;
11
(
2
):
294
.
20.
Klotz
U
.
Pharmacokinetics and drug metabolism in the elderly
.
Drug Metab Rev
.
2009
;
41
(
2
):
67
76
.
21.
Bauer
M
,
Goldstein
M
,
Heylmann
D
,
Kaina
B
.
Human monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant
.
PLoS One
.
2012
;
7
(
6
):
e39956
.
22.
Kourelis
TV
,
Buckner
JC
,
Gangat
N
,
Patnaik
MM
.
Temozolomide induced bone marrow suppression–A single institution outcome analysis and review of the literature
.
Am J Hematol
.
2015
;
90
(
9
):
E183
4
.
23.
Grant
LM
,
Kleiner
DE
,
Conjeevaram
HS
,
Vuppalanchi
R
,
Lee
WM
.
Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide
.
Dig Dis Sci
.
2013
;
58
(
5
):
1415
21
.
24.
Aygun
C
,
Altınok
AY
,
Çakır
A
,
Agan
AF
,
Balaban
Y
.
Acute temozolomide induced liver injury: mixed type hepatocellular and cholestatic toxicity
.
Acta Gastroenterol Belg
.
2016
;
79
(
4
):
487
9
.
25.
Schwarzberg
AB
,
Stover
EH
,
Sengupta
T
,
Michelini
A
,
Vincitore
M
,
Baden
LR
, et al
.
Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide
.
Cancer Invest
.
2007
;
25
(
4
):
249
55
.
26.
Gorospe Sarasúa
L
,
Ureña-Vacas
A
,
Muñoz Del Toro
JR
.
Pneumocystis jirovecii pneumonia complicating the progress of a patient with glioblastoma multiforme receiving temozolomide
.
Arch Bronconeumol
.
2016
;
52
(
10
):
534
5
.
27.
Krown
SE
,
Niedzwiecki
D
,
Hwu
W
,
Hodgson
L
,
Houghton
AN
,
Haluska
FG
, et al
.
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102)
.
Cancer
.
2006
;
107
(
8
):
1883
90
.
You do not currently have access to this content.